Ozempic and Wegovy have become two of the most talked-about medications in America. Millions of patients use these semaglutide-based drugs for diabetes management and weight loss. But now, a growing number of lawsuits and medical studies are raising serious concerns about a rare but potentially devastating eye condition linked to these medications: Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) — sometimes called an “eye stroke.”
Attorney Bill Bross breaks down these emerging claims, the science behind the allegations, and what patients need to know in this important video:
Watch the full video here:
What Is NAION?
NAION is a condition caused by reduced blood flow to the optic nerve. The result can be sudden, painless vision loss — sometimes permanent. According to researchers and ophthalmologists, patients may wake up with blurry vision, dark spots, or significant loss of sight in one eye.
Medical experts describe it as similar to a stroke affecting the optic nerve. Once damage occurs, vision loss is often irreversible.
Why Are Ozempic and Wegovy Being Investigated?
Recent studies have identified a possible association between semaglutide medications and increased risk of NAION. One widely discussed study from Mass Eye and Ear/Harvard researchers found patients prescribed semaglutide showed higher rates of NAION compared to patients using other medications.
Additional research from Europe and recent publications in ophthalmology journals have continued to explore the potential connection. Some studies suggest Wegovy users may face a higher relative risk than Ozempic users, though researchers caution that more evidence is still needed to establish direct causation.
Experts continue to emphasize:
- The condition remains rare
- Research is ongoing
- Patients should not stop medications without consulting their doctors
Lawsuits Are Rapidly Expanding
Across the United States, plaintiffs are filing lawsuits alleging that manufacturers failed to adequately warn patients about the potential blindness risk associated with semaglutide drugs.
According to legal reports:
- Federal multidistrict litigation (MDL) proceedings have been established for GLP-1 vision loss claims
- Additional state court consolidations are underway
- Plaintiffs allege manufacturers knew or should have known about the risk of NAION
- Many lawsuits focus on failure-to-warn allegations regarding Ozempic and Wegovy labeling
Patients involved in these cases report sudden vision loss, blindness, and permanent life changes after taking the medications.
Symptoms Patients Should Never Ignore
Anyone taking semaglutide medications should seek immediate medical attention if they experience:
- Sudden blurry vision
- Dark or shadowy vision
- Loss of peripheral vision
- Eye pain or pressure
- Sudden blindness in one eye
Early evaluation by an ophthalmologist may be critical.
Final Thoughts
GLP-1 medications have helped many patients manage diabetes and obesity, but the emerging reports surrounding NAION and blindness claims are drawing growing attention from both the medical and legal communities. While researchers continue studying the potential connection, patients deserve to stay informed about possible risks and warning signs.
